Since the HK-fbp1 vaccine candidate confers high protection against Cryptococcus neoformans infection prophylactically by inducing T cell-dependent protective immunity, we asked whether HK-fbp1 could be applied as a therapeutic agent to treat Cryptococcus-infected hosts by boosting their immunity. The gene discussed is FBP1; the disease is cryptococcosis.